The EU Commission imposes fines of € 16M on pharmaceutical companies for delaying market entry of generic pain-killer (Johnson & Johnson and Novartis)

European Commission imposes Fines of € 16 000 000 on Johnson & Johnson and Novartis for delaying Market Entry of generic Pain-Killer Fentanyl* On 10 December 2013, the European Commission imposed fines of € 10 798 000 on the US pharmaceutical company Johnson & Johnson (J&J) and € 5 493 000 on Novartis of Switzerland. In July 2005, their respective Dutch subsidiaries concluded an anticompetitive agreement to delay the market entry of a cheaper generic version of the pain-killer fentanyl

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Competition Network Brief, The EU Commission imposes fines of € 16M on pharmaceutical companies for delaying market entry of generic pain-killer (Johnson & Johnson and Novartis), 10 December 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 62153

Visites 213

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues